Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioGenesis PMR dispute panel cancelled

This article was originally published in The Gray Sheet

Executive Summary

Interactive review of new data, agreed to by FDA, allows cancellation of planned Aug. 20 medical device dispute resolution panel meeting, according to the firm. The MDDRP was intended to resolve the scientific dispute over CardioGenesis' pending PMA supplement for its PMR percutaneous myocardial revascularization system after FDA deemed the application "not approvable" last December (1"The Gray Sheet" March 3, 2003, p. 3). The MDDRP could be rescheduled if the dispute remains unresolved, the firm says...

You may also be interested in...

CardioGenesis gets “interactive”

Special FDA review of additional Axcis percutaneous myocardial revascularization system data supplied by the company will take "about eight to 10 weeks," the firm says Aug. 28. FDA deemed the device "not approvable" last December; a subsequent medical device dispute resolution panel was cancelled after the agency agreed to review additional data (1"The Gray Sheet" July 21, 2003, In Brief)...

CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review

CardioGenesis is retaining Covington & Burling to help prepare for its upcoming dispute resolution panel. The regulatory law firm consulted Lifecore Biomedical in the only other MDDRP review

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts